Hair growth can be induced without stopping DHT, as seen with Minoxidil. HMI115 may work by promoting follicle growth, not targeting the root cause of hair loss (DHT).
Rapamycin, finasteride, and minoxidil are discussed as a strategy for hair loss prevention and reversal. Pulsed dosing of rapamycin is suggested to avoid conflicting effects with minoxidil.
User shared 18-month progress using 1 mg finasteride daily and varying doses of oral minoxidil. Minoxidil caused side effects managed with taurine, dandelion root, sauna, and collagen.
Hair loss treatments, ranging from topical minoxidil and finasteride to taking hormones such as estradiol or nandrolone, as well as a controversial suggestion of an orchiectomy. A hair system is also mentioned as an alternative solution.
Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.
A user shared their experience with hair loss, using finasteride and minoxidil, and eventually undergoing a hair transplant of 1800 grafts. They regret not starting finasteride earlier and mention that despite the transplant, their scalp is still visible under strong light.
Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.
Significant hair improvement was achieved using 3mg Minoxidil and 1.2mg Finasteride over six months, with no side effects, leading to reconsideration of a hair transplant. A detailed skincare routine, including tretinoin and SPF, also improved skin appearance.
Minoxidil is more effective when combined with retinoic acid, such as tretinoin or tazarotene, enhancing hair growth. Some users experience significant regrowth, while others see minimal effects or side effects.
User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.
ET-02, a new hair loss treatment, shows promising results with a 6-fold increase in hair count, potentially outperforming minoxidil by activating stem cells in hair follicles. Further trials are ongoing to confirm its efficacy and safety, with potential market release in the future.
The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.
ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.
A 48-year-old man's 11-month progress using 1mg finasteride for hair loss treatment, with significant improvement and no side effects. Other users share their experiences, with some also seeing positive results, while others have not been as successful.
The conversation discusses the HMI-115 trial for hair loss, which was expected to end around July 2023 due to a late participant. Participants also mention Minoxidil, finasteride, and RU58841 as treatments.
The conversation discusses the potential of Verteporfin for hair regeneration and improving hair transplant surgery to leave no scars. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
Significant hair regrowth was achieved using RU58841, minoxidil, and microneedling during a high-dose steroid cycle. The user reported no side effects from RU58841 and plans to continue the regimen.
Han Bio plans to start Phase 1 clinical trials for a hair growth treatment in 2027 after successful results in mice. Many users express skepticism about the effectiveness of treatments that work on mice but not on humans, and discuss existing treatments like finasteride and minoxidil.
A 36-year-old has been using 1mg oral finasteride daily and minoxidil foam twice daily for 18 months, experiencing significant hair regrowth with no side effects. Initial shedding occurred, but noticeable improvements began around 11 months, with major changes by 16 months.
A user shared progress pictures after 50 days of using a compound with 10% minoxidil, 0.1% finasteride, and biotin, expressing satisfaction with the results. Another user commented positively on the progress.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
User shared 16-month progress using finasteride 1 mg/day and minoxidil 5% solution once/day, noting significant regrowth, especially in temporal peaks. Users discussed shedding, side effects, and positive feedback from others.
Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.
The conversation discusses the potential use of verteporfin for hair loss treatment, with one user mentioning their surgeon's interest in trying it and another noting its research status and clinical use as a YAP inhibitor. Some users debate the market size, availability of generics, and the optimism in the hair loss community regarding new treatments.
The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.
A user shared their 1.5-year progress after a FUE crown transplant, using dutasteride and oral minoxidil, which improved their hairline and stabilized hair loss. They experienced dizziness from topical minoxidil but had no side effects from finasteride, dutasteride, or oral minoxidil.
ABS-201, a prolactin receptor blocker, shows promise in reversing hair loss and graying, with early success in macaques. Current treatments like finasteride, minoxidil, and RU58841 are still widely used, but new options like PP405 are eagerly anticipated.